Scorpius Holdings Inc. · OTC:SCPX
Scorpius — Heat Biologics — Investor Presentation (June 2015)
17 slides from Scorpius's investor presentation, Jun 15, 2015
Slide 1: Introduction of ComPACT: Combination Pan-Antigen Cytotoxic Therapy
Introduction of ComPACTCombination Pan-Antigen Cytotoxic Therapy June 15, 2015
Slide 2: ImPACT Immunotherapy Platform
ImPACT Immunotherapy PlatformSpecifically Activates Pan-Antigen CD8+ T-Cells to Kill Tumor Cells * Intradermal InjectedImPACT Cells ① ImPACT cells secrete Gp96-Ig chaperone + tumor antigens (TAA) ② Dual antigen carrier & adjuvant activates Dendritic Cells ③ Selectively activate CD8+ T-Cells ④ CD8+ T
Slide 3: Combination Immunotherapy Design Objectives
Combination Immunotherapy Design Objectives We all know that combination immunotherapy will provide superior clinical benefit than any single checkpoint, co-stimulator or vaccine can as monotherapy. How can we implement combination therapy:1. In the simplest and most efficacious way2. With the lowes
Slide 4: Design: Combination Pan-Antigen Cytotoxic Therapy
ComPACT DesignCombination Pan-Antigen Cytotoxic Therapy *
Slide 5: gp96-Ig Fc-OX40L
gp96-Ig Fc-OX40L *
Slide 6: Construct Prioritization Scheme
Construct Prioritization Scheme There are multiple co-stimulatory receptors that may synergize with gp96-Ig based vaccines. Feasibility was performed by examining the immune response in animals treated with vaccine in combination with agonist antibodies *
Slide 7: Characterization
ComPACT Characterization ImPACT Vaccine << HLA A1 nen = — _— = ) 8 Secreted Ova (ng/mL} 8 Secreted IgG (ng/mL) ° ComPACT Vaccine Gp96-Ig ;OX40L-Fe MiControl MnPACT HI ComPACT +++ p<,0001 vs. Ova Only mRNA Fold Expression
Slide 8: Feasibility Question
Feasibility Question Antibodies rapidly distribute systemically, and produce systemic effectsWith ComPACT, Fc-OX40L is local just in the injection siteCan high enough concentrations be achieved to have an effect? *
Slide 9: Enhances CD8 Proliferation
ComPACT Enhances CD8 Proliferation Following primary immunization, locally secreted Fc-OX40L (in ComPACT) produces superior antigen-specific CD8+ T cell expansion than vaccines combined with OX40 antibodies *
Slide 10: Kinetics of CD8+ T Cell Response
Kinetics of CD8+ T Cell Response *
Slide 11: Increases Specificity
ComPACT Increases Specificity ComPACT leads to increased antigen-specific CD8 cellsOX40 antibodies also lead to non-specific increases in CD4 cells and T regulatory cells *
Slide 12: Increases CD8+ Memory
ComPACT Increases CD8+ Memory The increase in antigen-specific CD8 cells seen with ComPACT is associated with an increase in memory precursor cells (CD127+KLRG1-), not seen with OX40 antibodies *
Slide 13: Increases Ag-Specific CD8+ Activation
ComPACT Increases Ag-Specific CD8+ Activation OX40 antibodies lead to increased activation of both Ag-specific and non-specific CD8, while ComPACT activates only Ag-specific CD8 cells *
Slide 14: Therapeutic Tumor Immunity
Therapeutic Tumor Immunity ComPACT leads to improved survival in a mouse colon cancer model, similar to OX40 antibody combined with vaccine *
Slide 15: Summary
Summary Incorporation of OX40L-Fc into a gp96-Ig vaccine vector is feasibleThis construct leads to enhanced antigen-specific immunity at both priming and boostingThe immune-stimulatory effect of ComPACT is superior to separate administration of vaccine and OX40 agonist antibodyThis is due to enhance
Slide 16: Vide “
ComPACT Vide “ “* >
Slide 17: Heat Biologics
“Heat Biologics